IFNA2 and melanoma: Four prospective trials in Atkins’ observation study [16] showed that in patients with high-risk resection of melanoma, adjuvant therapy with high-dose interferon-alpha-2b can effectively improve the relapse-free survival rate but not the overall survival rate.